Roche data at ESMO 2025 showcase advances in science and cancer care across multiple tumour types roche.com
Roche receives CE Mark for AI-based Kidney Klinrisk Algorithm(1) and launches new comprehensive chronic kidney disease (CKD) algorithm panel roche.com
FDA approves Roche’s Tecentriq plus lurbinectedin as first-line maintenance therapy for extensive-stage small cell lung cancer roche.com
Roche commences tender offer for all shares of 89bio, Inc. for $14.50 per share in cash, plus a non-tradeable contingent value right for up to $6.00 per share in cash roche.com
Data show Roche’s sixth-generation Troponin T test offers a new level of accuracy critical for diagnosing heart attacks roche.com
Roche presents new data for OCREVUS and fenebrutinib across broad patient populations at ECTRIMS 2025 roche.com
Positive phase III results show Roche’s giredestrant significantly improved progression-free survival in ER-positive advanced breast cancer roche.com
CHMP recommends EU approval of Roche’s subcutaneous formulation of Lunsumio for people with relapsed or refractory follicular lymphoma roche.com
Roche enters into a definitive merger agreement to acquire 89bio, and its phase 3 FGF21 analog for the therapy of moderate to severe MASH roche.com
